Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 10/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825414 | 0.94 | BCHE (0.53) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL14825400 | 0.87 | BCHE (0.50) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL14825415 | 0.82 | BCHE (0.54) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL14825407 | 0.81 | OPRD1 (0.55) | KCNH2HRH3LMNASMN1; SMN2EPHX2 | |
| SCHEMBL14825134 | 0.77 | BCHE (0.48) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL14825310 | 0.77 | GSK3B (0.48) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL9353069 | 0.77 | BCHE (0.56) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL14825117 | 0.77 | BCHE (0.49) | BCHEGRM5GRM7GRM3CHRM2 | |
| SCHEMBL8177110 | 0.76 | HRH3 (0.55) | HRH3LMNAHTTSMN1; SMN2 | |
| SCHEMBL12065122 | 0.76 | BCHE (0.48) | BCHEGRM5GRM7GRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | BCHE 2942/4885GRM5 256/4885GRM7 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.